AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01946984
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02622685
Drug: DWP10292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DWP10292 tablets, oral administration, multiple administration
Trial: NCT02622685
Drug: DWP10292 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, oral administration, multiple administrations
Trial: NCT02622685
Drug: UDCA Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, oral administration, multiple administrations
Trial: NCT01908894
Drug: BIOD-123
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00789165
Drug: no therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy; this is not a placebo-controlled trial
Trial: NCT00455026
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: target effect site concentration during induction
Trial: NCT01048463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
Trial: NCT01048463
Drug: HDEPA
RxNorm normalized name: Hydroxyethyl Diethylenetriamine Pentaacetic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
Trial: NCT01048463
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
Trial: NCT00161681
Drug: Levonorgestrel/Ethinyl Estradiol
RxNorm normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01961388
Drug: Bay G5421 Glucobay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, dosage of Acarbose as per the directions of treating physician
Trial: NCT01202877
Drug: PKC412
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
Trial: NCT01295086
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/² continuously
Trial: NCT02341521
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally for 8 days
Trial: NCT01351350
Drug: MLN0128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN0128 capsules
Trial: NCT00186823
Drug: TBI, systemic chemotherapy and antibodies as follows:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
Trial: NCT01684878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
Trial: NCT00938145
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
Trial: NCT00642941
Drug: RG1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
Trial: NCT03376620
Drug: 1,4-Diaminobutane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application to surgical breast scars of 1,4 diaminobutane on the active side
Trial: NCT03376620
Drug: 10% Urea cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application to surgical breast scars of 10% Urea cream on the sham side
Trial: NCT03221231
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily, placebo
Trial: NCT00304707
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02355756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01255657
Drug: ABT-806
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-806 will be administered by intravenous infusion.
Trial: NCT02903238
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose capsule
Trial: NCT05209906
Drug: Fentanyl Buccal Soluble Film
RxNorm normalized name: fentanyl Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.
Trial: NCT02985879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
Trial: NCT01553201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, 4cc, one time intramuscular administration
Trial: NCT04704271
Drug: Inhaled THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg inhaled THC
Trial: NCT04704271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo (no active cannabinoids)
Trial: NCT02291471
Drug: T0001，10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02291471
Drug: T0001，20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02291471
Drug: T0001，35mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02291471
Drug: T0001，50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02356991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02709486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00737737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00571194
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study
Trial: NCT03829150
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin (Klaricid) 500 mg bid for 7 days
Trial: NCT03221400
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 2400 mg/m2 IV
Trial: NCT01777256
Drug: GSK2586184 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
Trial: NCT01777256
Drug: GSK2586184 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
Trial: NCT01777256
Drug: GSK2586184 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
Trial: NCT01777256
Drug: GSK2586184 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
Trial: NCT00856713
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of 2 mg NRL972
Trial: NCT01777256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet will be administered orally twice daily up to 12 weeks.
Trial: NCT05732181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patch without drugs
Trial: NCT01000610
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25 mg weekly (oral or parenteral)
Trial: NCT00363155
Drug: KRN7000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02205502
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02932020
Drug: 0.5% marcaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epidural injection of 2mL 0.5% marcaine
Trial: NCT01402180
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01754818
Drug: Bendavia 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01754818
Drug: Bendavia 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01754818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00500006
Drug: MK0457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour.
Trial: NCT02216799
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
Trial: NCT01213836
Drug: Placebo matching Seroquel IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
Trial: NCT02507245
Drug: Growth Hormone-Releasing Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
Trial: NCT04049123
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01559935
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Trial: NCT04374799
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two doses of heparin
Trial: NCT01431352
Drug: Chinese herbal medicine granules or Chinese herbal medicine granules placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day for 6 month
Trial: NCT01057654
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg
Trial: NCT00523328
Drug: BG9924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage administered as per Biogen-idec protocol
Trial: NCT01764867
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Trial: NCT04004117
Drug: Fentanyl citrate solution sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
Trial: NCT04004117
Drug: Placebo oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
Trial: NCT04663438
Drug: Chemotherapy Drugs, Cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
Trial: NCT03269799
Drug: Vitamin C 500 MG Oral Capsule
RxNorm normalized name: vitamin C 500 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
Trial: NCT01139749
Drug: oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules of 20 mg a day, every other day, for six months
Trial: NCT03333499
Drug: YanXinShi placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure
Trial: NCT03333499
Drug: YanXinShi pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure
Trial: NCT01602471
Drug: [F-18]RDG-K5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately fifteen (15) patients with carotid artery stenosis \> 69% will undergo an endarterectomy and will be imaged under PET/CT with \[F-18\]RGD-K5
Trial: NCT03590379
Drug: CHF5993 pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/GB pMDI
Trial: NCT04727684
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage adjustment according to the ovarian response.
Trial: NCT03590379
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 5993 DPI matched placebo
Trial: NCT00956787
Drug: AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
Trial: NCT03840499
Drug: Optimal medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy
Trial: NCT01891305
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03382431
Drug: Placebo/vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat doses
Trial: NCT03590379
Drug: Placebo pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
Trial: NCT00854802
Drug: Debio 025 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio 025 placebo supplied in soft gel capsules
Trial: NCT04104984
Drug: Tocolytic Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a medication is given to prevent uterine contraction
Trial: NCT02065713
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
Trial: NCT02065713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
Trial: NCT03715322
Drug: Tobramycin Inhalant Product
RxNorm normalized name: tobramycin Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
Trial: NCT03715322
Drug: Natural saline inhalation
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
Trial: NCT03887416
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
Trial: NCT04781114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
Trial: NCT02336516
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
Trial: NCT02336516
Drug: Placebo (glucose solution 10%)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03235479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet to match rimegepant dose QD
Trial: NCT01048502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
Trial: NCT03989531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip infusion over 60 minutes
Trial: NCT03662763
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00467831
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
Trial: NCT00467831
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin tablet, 333 mg by mouth three times daily.
Trial: NCT03553875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
Trial: NCT01754987
Drug: Ascorbic Acid + Sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01076556
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02251977
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
Trial: NCT02251977
Drug: mFOLFOX6 or XELOX
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient.
Trial: NCT04532957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsules
Trial: NCT01267006
Drug: GSK1325756
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
Trial: NCT01267006
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
Trial: NCT00670033
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo
Trial: NCT00479388
Drug: Comparator: simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin (20mg to 40mg) for 12 weeks.
Trial: NCT02018094
Drug: Co-amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
Trial: NCT02018094
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
Trial: NCT00382629
Drug: BHT-3009 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00382629
Drug: BHT-3009 1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00382629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no